Pilot Study of Intravenous Administration of the Acid-Treated Salmonella Minnesota R595 (Re) in Cancer Patients

The clinical toxicity of acetic acid-treated « Salmonella minnesota » R595 (Re) organisms was evaluated in 24 cancer patients. Bacteria were injected i.v. four times at increasing doses for a total of 6.5 μg. This therapeutic regimen was free of major side effects (one patient had fever higher than 38 °C and 10 patients complained of pruritus). Furthermore, this bacterial preparation which possesses a more exposed lipid A on its surface, exhibited immunomodulating capacities in that it normalized the inverted T helper/T suppressor ratio and enhanced natural killer activity in tumor patients. The mechanisms of the lower toxicity and immunomodulating activities of these bacteria compared to other lipid A preparations are discussed.

[1]  C. Galanos,et al.  Relationship between immune system and gram-negative bacteria. Acid-treated Salmonella minnesota R595 (Re) enhances immune responsiveness in patients with gynecologic malignancies. , 1986, International journal of immunopharmacology.

[2]  G. Miragliotta,et al.  In Vitro Generation of Procoagulant Activity by Corynebacterium parvum‐Stimulated Mononuclear Leukocytes , 1985, Journal of leukocyte biology.

[3]  N. Qureshi,et al.  Lipid A and immunotherapy. , 1984, Reviews of infectious diseases.

[4]  I. Penn.  Depressed immunity and the development of cancer. , 1981, Clinical and experimental immunology.

[5]  D. Nelson,et al.  Cancer and subversion of host defences. , 1981, The Australian journal of experimental biology and medical science.

[6]  H. Bingham.  Comparison of immune derangements in patients with different malignancies , 1980 .

[7]  C. Galanos,et al.  Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats. , 1980, Infection and immunity.

[8]  J. Fahey,et al.  Comparison of immune derangements in patients with different malignancies , 1980, Cancer.

[9]  E. Reinherz,et al.  Human T lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. A comparison , 1980, The Journal of experimental medicine.

[10]  B. Bonavida,et al.  Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. , 1979, Journal of immunology.

[11]  T. Waldmann,et al.  The suppressor-cell network in cancer (second of two parts). , 1978 .

[12]  R. Ulevitch,et al.  The effects of bacterial endotoxins on host mediation systems. A review. , 1978, The American journal of pathology.

[13]  O. Vos.  Effect of bacterial lipopolysaccharide on proliferation of CFU-S. , 1978, Experimental hematology.

[14]  Z. Cohn.  Activation of mononuclear phagocytes: fact, fancy, and future. , 1978, Journal of immunology.

[15]  D. Carlo,et al.  A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. , 1978, Analytical biochemistry.

[16]  R. Snyderman,et al.  Abnormalitieis of monocyte chemotaxis in patients with melanoma: effects of immunotherapy and tumor removal. , 1977, Journal of the National Cancer Institute.

[17]  E. Rietschel,et al.  Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis , 1977, Infection and immunity.

[18]  R. Snyderman,et al.  Abnormalities of Monocyte Chemotaxis in Patients With Melanoma: Effects of Immunotherapy and Tumor Removal , 1977 .

[19]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Galanos,et al.  Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. , 1971, European journal of biochemistry.